CVS, Nio, WM: Trending Analyst Moves Investors Must See

Analysts are intrested in these 5 stocks: ( (CVS) ), ( (NIO) ) and ( (WM) ). Here is a breakdown of their recent ratings and the rationale behind them.

CVS Health is back in analysts’ good graces as Bernstein’s Lance Wilkes upgrades the stock to Outperform, seeing a path to more stable earnings and a higher valuation. His new fair value mark of $94 per share suggests meaningful upside from the recent $75.72 close, underpinned by easing policy risks and growing confidence in management’s turnaround plan.

The big swing factor is Aetna, CVS’s insurance arm, where Wilkes expects earnings to nearly double over the next three years as Medicare Advantage margins normalize. With the recent PBM reform bill and the first FTC settlement in the sector acting as “clearing events,” he believes the overhang on the pharmacy benefits business is fading and that the stock’s earnings multiple can grind higher.

Near term, 2026 isn’t about explosive growth but about resilience, as PBM model margin pressure is likely to offset the improving profitability at Aetna. The payoff, in his view, comes from 2027 onward, where he projects EPS resuming growth at roughly a 9% annual clip through 2029, driven by faster expansion in Aetna and steadier results in the retail pharmacies.

Crucially for valuation-focused investors, the upgrade case hinges on both earnings and the multiple, not just one or the other. Wilkes now values CVS at about 12x next‑twelve‑months EPS, slightly above his prior 11.7x, reflecting a belief that the combination of regulatory clarity and insurance margin recovery justifies a modest re‑rating.

For investors who shunned CVS over PBM regulatory fears, this call signals a potential inflection point where risk is shifting from unknowns to execution. If Aetna’s Medicare Advantage turnaround stays on track and PBM reforms don’t bite harder than expected, the analyst sees catalysts in 2026‑2027 that could push the stock into a new, more stable growth phase.

Nio is drawing fresh enthusiasm as HSBC’s Yuqian Ding upgrades the Chinese EV maker to Buy, highlighting a new product cycle, better model mix, and clearer visibility on profits. Her new U.S. dollar target price of $6.80, up from $4.80 and above the current $5.47 level, reflects higher conviction that Nio’s recent momentum can evolve into sustainable growth.

The turning point came in 4Q25, when Nio posted its first quarterly net profit, helped by a 71% year‑on‑year surge in deliveries and tighter cost control. Vehicle gross margin climbed to 18.1% thanks largely to strong ES8 sales, while spending on SG&A and R&D fell 15% quarter‑on‑quarter, signaling the company can grow volumes without losing discipline on expenses.

Ding expects 2026 to bring more than just incremental progress, with new models like the ES9 and ONVO L80 plus a large SUV planned to further lift volumes and support a richer product mix. Early 2026 deliveries, up 77% year‑on‑year despite weakness in the broader EV market, suggest Nio is gaining share in the higher‑priced segment above RMB200k, which has been more resilient through subsidy shifts.

Her team has raised 2026‑27 volume and earnings forecasts and now anticipates Nio reaching operating profit breakeven for full‑year 2026. That revision puts their revenue and earnings estimates 15% and 80% above current consensus, respectively, underscoring how much more optimistic they’ve become versus the broader market.

For investors watching cash burn and profitability risk in Chinese EVs, the thesis is that Nio is graduating from a story of scale at any cost to one of profitable growth. Ding’s upgraded target prices on both U.S. and Hong Kong listings imply more than 20% upside, assuming management can deliver on the new model launches and maintain strict cost control.

Waste Management, the industry heavyweight known simply as WM, is getting fresh coverage from Wolfe Research’s Brad Hewitt, but without the excitement of a bold bullish call. He initiates at Peer Perform, essentially a Hold stance, with a fair value range stretching from $202 to $321 and a view that the company will continue its steady, rather than spectacular, growth path.

Hewitt describes WM as a behemoth with a powerful competitive moat built on vertical integration and a dominant position in U.S. landfills, owning about 30% of national capacity. That footprint gives it pricing power and supports the familiar playbook of mid‑single to high‑single‑digit EBITDA growth and low double‑digit EPS growth, but he does not see the stock as fundamentally mispriced.

On the company’s 2027 financial targets, set at its 2025 investor day, Hewitt is slightly more cautious than management. His model sits a few percentage points below WM’s revenue and EBITDA goals, while running modestly above on free cash flow, suggesting he expects strong cash generation even if top‑line growth underwhelms.

From a valuation angle, WM trades at roughly 14.3x next‑twelve‑month EV/EBITDA, right in line with its one‑ and five‑year medians and only a small discount to peers. Hewitt’s base case assumes a modest 0.5‑turn multiple expansion by the end of 2026, which could narrow the valuation gap versus Republic Services, but not enough to justify an outright bullish stance.

For investors seeking defensive exposure and predictable cash flows, WM still looks like a core holding rather than a high‑beta trade. The new coverage reinforces the idea that while recycling, renewable natural gas, and medical waste may add incremental growth, the real story is consistency, not dramatic upside surprises.